Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Terminated 1Recruiting 1No longer available 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 28Carboplatin 13Nivolumab 12Cisplatin 12atezolizumab 10Paclitaxel 10venetoclax 9Ipilimumab 9Radiotherapy 8Pemetrexed 8Docetaxel 8fludarabine 7durvalumab 7Specimen Handling 7Gemcitabine 7Cyclophosphamide 7Bevacizumab 7fludarabine phosphate 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6tislelizumab 5enzalutamide 5Trastuzumab 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5tazemetostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × ceritinib × 90 days × Clear all
NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 17 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡